CONFIRM Trial

The CONFIRM Trial (Cancer Research UK NivOlumab vs placebo For Relapsed Mesothelioma) was a UK-based, randomized, double-blind, placebo-controlled Phase III clinical trial that tested the immunotherapy drug nivolumab in patients with mesothelioma that had progressed after prior chemotherapy. Published in 2021 by Fennell and colleagues in The Lancet Oncology, it was the first randomized trial to show that an immune checkpoint inhibitor improved overall survival and progression-free survival as a second- or third-line treatment for relapsed mesothelioma.

Origin

The trial was designed and led by Professor Dean Fennell at the University of Leicester and run through the UK National Cancer Research Institute Mesothelioma Clinical Studies Group, with results published in 2021. Its name is an acronym derived from its full title and reflects the goal of confirming whether nivolumab, already studied in earlier single-arm work, produced a real survival benefit when tested against placebo.

Significance in Asbestos Context

For patients whose mesothelioma has come back after first-line chemotherapy (historically pemetrexed plus platinum), CONFIRM helped establish nivolumab as an evidence-based treatment option where, for years, there was no proven second-line therapy. The trial is frequently cited in oncology guidelines and treatment discussions, and it shapes what options your medical team may offer if your disease progresses. In a legal context, the cost of immunotherapy and the extension of survival are both relevant to damages, including medical expenses and loss of earnings, so records of any nivolumab treatment you receive, including whether it was prescribed based on CONFIRM-era evidence, can matter to your claim.

Example Sentence

After her mesothelioma progressed on chemotherapy, her oncologist discussed the CONFIRM Trial results and recommended nivolumab as a second-line treatment.

Related Terms

Nivolumab, Immunotherapy, Checkpoint Inhibitor, Pemetrexed, CheckMate 743, Pleural Mesothelioma

Notes

• If you have relapsed mesothelioma, ask your oncologist whether nivolumab, supported by the CONFIRM Trial, is an appropriate option for your case and whether your tumor type (epithelioid, sarcomatoid, or biphasic) affects expected benefit.
• Keep copies of all treatment records, infusion logs, and pharmacy bills for immunotherapy; these document both medical decision-making and out-of-pocket or insurance-paid costs that may be recoverable.
• Ask about side-effect monitoring (immune-related adverse events affecting the lungs, liver, thyroid, and bowel) and make sure these are documented in your chart, as they can affect both ongoing care and damages claims.
• If you are considering or already in litigation, tell your legal team about any immunotherapy treatment so future treatment costs and prognosis evidence are properly accounted for in your case.